NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 362 filers reported holding NOVOCURE LTD in Q2 2021. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $466,283 | +44.8% | 28,872 | +272.1% | 0.00% | 0.0% |
| Q2 2023 | $322,041 | -62.5% | 7,760 | -45.7% | 0.00% | -50.0% |
| Q1 2023 | $858,979 | +72756.6% | 14,283 | -11.1% | 0.00% | -33.3% |
| Q4 2022 | $1,179 | -99.9% | 16,061 | +1.5% | 0.00% | -25.0% |
| Q3 2022 | $1,203,000 | +10.0% | 15,831 | +0.5% | 0.00% | +33.3% |
| Q2 2022 | $1,094,000 | -4.0% | 15,746 | +82.7% | 0.00% | 0.0% |
| Q1 2021 | $1,139,000 | -4.6% | 8,619 | +24.9% | 0.00% | -25.0% |
| Q4 2020 | $1,194,000 | +37.7% | 6,899 | -11.4% | 0.00% | +33.3% |
| Q3 2020 | $867,000 | +238.7% | 7,787 | +80.4% | 0.00% | +200.0% |
| Q2 2020 | $256,000 | -2.3% | 4,316 | +10.9% | 0.00% | 0.0% |
| Q1 2020 | $262,000 | +21.9% | 3,891 | +52.8% | 0.00% | 0.0% |
| Q4 2019 | $215,000 | -14.7% | 2,546 | -24.5% | 0.00% | 0.0% |
| Q3 2019 | $252,000 | – | 3,373 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $39,681,000 | 20.12% |
| HARTLINE INVESTMENT CORP/ | 330,672 | $27,866,000 | 5.97% |
| MORGAN JESS S & CO INC | 52,889 | $4,457,000 | 4.37% |
| Darsana Capital Partners LP | 1,350,000 | $113,765,000 | 3.88% |
| Rhenman & Partners Asset Management AB | 350,000 | $29,495,000 | 3.23% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $843,000 | 2.55% |
| Taylor Frigon Capital Management LLC | 38,073 | $3,208,000 | 2.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,500 | $2,991,000 | 1.08% |
| Granite Investment Partners, LLC | 261,315 | $22,021,000 | 1.04% |
| Nicholas Investment Partners, LP | 85,835 | $7,233,000 | 0.74% |